On August 26th, 2020, Bonnie J Addario Lung Cancer Foundation reported that the Food and Drug Administration (FDA) approved the FoundationOne Liquid CDx for comprehensive liquid biopsy biomarker testing for patients with any solid tumor (Press release, Bonnie J Addario Lung Cancer Foundation, AUG 26, 2020, View Source [SID1234564229]). The FDA based their approval on analysis from multiple clinical validation studies which showed that FoundationOne Liquid CDx is very sensitive and specific in finding mutations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This approval gives patients more options for comprehensive liquid biopsy biomarker testing that were not previously available.